All In Biotech

Drug Trial Radar · NCT00605683

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Last checked: Nov 19, 2026Latest source record: Oct 29, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 679 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

679

Actual

Start

Nov 2007

Primary completion

Jan 2012

Study completion Mar 2012

Sponsor

Lead sponsor
Newron Pharmaceuticals SPAIndustry
Sponsor type
Industry
First posted
Jan 31, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that crosses the blood brain barrier, and also to the use of selective inhibitors of MAO B, the major DA metabolising enzyme in man. This is a double-blind, placebo-controlled, parallel-group, randomised, multi-centre, multi national, Phase III trial, comparing two doses of safinamide (50 and 100 mg p.o. q.a.m.) versus placebo as add-on therapy to a stable dose of a single dopamine agonist in subjects with early idiopathic Parkinson's Disease. The principal efficacy measure, i.e., change in mean value of UPDRS - Section III total score from baseline to endpoint, was chosen based on regulatory guidance and prior use in other trials in similar populations.

Conditions

  • Idiopathic Parkinson's Disease

Interventions

  • Safinamide (as add-on therapy)Drug

    Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative

  • Safinamide (as add-on therapy)Drug

    Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist

  • Safinamide (as add-on therapy)Drug

    Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the changes from baseline to W24 in motor symptoms (UPDRS Section III).Time frame: 24 weeks

Locations

125 sites in 20 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Arizona Neurological Institute

    Phoenix, Arizona

  • Pacific Neuroscience Medical Group

    Oxnard, California

  • San Francisco Clinical Research Center

    San Francisco, California

  • Parkinson's Institute

    Sunnyvale, California

  • Institute for Neurodegenerative Disorders

    New Haven, Connecticut

  • Parkinson's Disease and Movement Disorder Center

    Boca Raton, Florida

  • Neurologic Consultants P.A.

    Fort Lauderdale, Florida

  • University Of Florida

    Gainesville, Florida

  • Parkinson's Disease Treatment Center of SW Florida

    Port Charlotte, Florida

  • Neurology Clinical Research Inc.

    Sunrise, Florida

  • University Of South Florida Medical Center

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Medical College of Georgia

    Augusta, Georgia

  • Columbus Research Institute

    Columbus, Georgia

  • Northwestern University PD and Movement Disorders Center

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Boston University School of Medicine

    Boston, Massachusetts

  • Parkinson's Disease and Movement Disorders Center of Albany

    Albany, New York

  • North Shore Medical Center

    Manhasset, New York

  • Columbia University Medical Center

    New York, New York

  • New York University

    New York, New York

  • The Neurological Institute

    Charlotte, North Carolina

  • Duke University Health Systems

    Druham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Neurology Specialists

    Dayton, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Lankenau Hospital

    Wynnewood, Pennsylvania

  • Butler Hospital

    Providence, Rhode Island

  • Baylor College of Medicine

    Houston, Texas

  • Hospital Español

    Buenos Aires, Argentina

  • Instituto de Neurociencias Buenos Aires S.A.

    Buenos Aires, Argentina

  • Clinica IMECO

    Capital Federal, Argentina

  • Hospital Italiano de Buenos Aires

    Capital Federal, Argentina

  • Instituto de Investigaciones Neurológicas Raul Carrea FLENI

    Capital Federal, Argentina

  • Instituto Frenopatico S.A.

    Capital Federal, Argentina

  • Instituto Argentino de Investigacion Neurologica SRL

    Ciudad Autonoma de, Argentina

  • Instituto Medico Congreso

    Ciudad Autonoma de Bs. As., Argentina

  • Instituto INEBA

    Ciudad Autónoma de Bs. As., Argentina

Showing 40 of 125 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.